Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Bolzano – page 2

29 clinical trials in Bolzano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Bolzano at a glance
29
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

29 trials in Bolzano

Open in trial search

Plasma cell myeloma refractory

Not yet recruiting

Study of teclistamab plus autologous lymphocyte infusion in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

IgA nephropathy

Not yet recruiting

Study on Corticosteroids, Dapagliflozin, and Drug Combination for Proteinuria in IgA Nephropathy Patients with Active or Chronic Kidney Lesions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Fondazione Schena Centro Europeo Della Ricerca Sulle Malattie Renali

Colitis ulcerative

Not recruiting

Study on the Effects of Eclitasertib in Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Eclitasertib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Bladder cancer

Not recruiting

Study of Pembrolizumab and BCG for Patients with High-Risk Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Oropharyngeal cancer+1

Not recruiting

Study on Electrochemotherapy with Bleomycin for Patients with Recurrent Oral and Oropharyngeal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin Sulfate
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Plasma cell myeloma

Not recruiting

Study on Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Universita' Degli Studi Di Torino

Polymyalgia rheumatica

Not recruiting

Study on Baricitinib for New-Onset Polymyalgia Rheumatica Patients to Reduce Steroid Use

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Medical University Of Vienna

Acute lymphocytic leukaemia

Not recruiting

Study of inotuzumab ozogamicin and drug combination in adult patients with B-cell Acute Lymphoblastic Leukemia who have minimal residual disease before stem cell transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Triple negative breast cancer

Not recruiting

Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Universita Degli Studi Di Padova

Hormone-refractory prostate cancer+1

Not recruiting

Study on Radium-223, Docetaxel, and Prednisone for Patients with Bone-Only Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Philadelphia positive acute lymphocytic leukaemia

Not recruiting

Study on Ponatinib and Blinatumomab for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Plasma cell myeloma

Not recruiting

Study of Daratumumab with Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Eligible for High-Dose Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Bolzano

What the registry says about research in the country

01 Hematologic Oncology

Groundbreaking research focusing on various blood cancers, including Multiple Myeloma and Acute Lymphoblastic Leukemia. Studies evaluate innovative treatment combinations and novel therapeutic approaches.

  • Multiple Myeloma Treatment Strategies
  • Leukemia Therapy Optimization
  • Stem Cell Transplantation

Several trials are investigating targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Solid Tumors

Comprehensive research into various solid cancers, including breast cancer, prostate cancer, and head and neck malignancies. Studies focus on targeted therapies and novel treatment combinations.

  • Advanced Breast Cancer Treatments
  • Colorectal Cancer Therapy
  • Bladder Cancer Management

Trials explore personalized medicine approaches based on genetic markers and innovative drug combinations.

03 Autoimmune Conditions

Clinical investigations of Polymyalgia Rheumatica and other autoimmune disorders, evaluating new biological treatments and therapeutic strategies.

  • Inflammatory Disease Management
  • Novel Biological Therapies
  • Long-term Treatment Safety

Research focuses on improving treatment outcomes while minimizing steroid dependency.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.